A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

The invention relates to the field of medicine and to the chemical and pharmacological industry, and concerns medicaments for the treatment of breast cancer. In particular the invention relates to a use of 3-O-sulfamoyloxy-7β-methyl-D-homo-6-oxa-8α-estra-1,3,5(10)-trien-17a-one as an anti-cancer agent in monotherapy and adjuvant therapy of breast cancer, including the triple negative breast cancer, and a method for the production of the said agent.

The invention relates to the field of medicine and to the chemical and pharmacological industry, and concerns medicaments for the treatment of breast cancer. In particular the invention relates to a use of 3-O-sulfamoyloxy-7β-methyl-D-homo-6-oxa-8α-estra-1,3,5(10)-trien-17a-one as an anti-cancer agent in monotherapy and adjuvant therapy of breast cancer, including the triple negative breast cancer, and a method for the production of the said agent.

Chromatography systems and methods for using carbon dioxide to separate one or more cannabis-derived compounds from other components of a mixture are generally described. Some of the methods described herein comprise transporting a mixture comprising a first cannabis-derived compound and one or more other components through a chromatography column containing a stationary phase comprising a packing material. In some embodiments, the mixture is transported through the column within a mobile phase that comprises carbon dioxide (e.g., supercritical CO.sub.2, liquid CO.sub.2). The mobile phase may be substantially free of a co-solvent that is in liquid phase at standard room temperature and pressure. In some embodiments, the mobile phase is free of any co-solvent and comprises 100 vol % carbon dioxide. The first cannabis-derived compound may interact with the stationary phase and/or the mobile phase to a different degree than the one or more other components of the mixture, causing at least partial separation of the first cannabis-derived compound from the one or more other components within the column. Due to this separation, at least one fraction of the mobile phase that comprises the first cannabis-derived compound and is substantially free of the one or more other components of the mixture may be collected.

Chromatography systems and methods for using carbon dioxide to separate one or more cannabis-derived compounds from other components of a mixture are generally described. Some of the methods described herein comprise transporting a mixture comprising a first cannabis-derived compound and one or more other components through a chromatography column containing a stationary phase comprising a packing material. In some embodiments, the mixture is transported through the column within a mobile phase that comprises carbon dioxide (e.g., supercritical CO.sub.2, liquid CO.sub.2). The mobile phase may be substantially free of a co-solvent that is in liquid phase at standard room temperature and pressure. In some embodiments, the mobile phase is free of any co-solvent and comprises 100 vol % carbon dioxide. The first cannabis-derived compound may interact with the stationary phase and/or the mobile phase to a different degree than the one or more other components of the mixture, causing at least partial separation of the first cannabis-derived compound from the one or more other components within the column. Due to this separation, at least one fraction of the mobile phase that comprises the first cannabis-derived compound and is substantially free of the one or more other components of the mixture may be collected.

Disclosed herein are methods for converting cannabidiol, cannabidiolic acid and analogs thereof into Δ.sup.8-tetrahydrocannabinol, Δ.sup.8-tetrahydrocannabinolic acid and analogs thereof. In particular, there is provided a method for converting a compound of Formula (I) as defined herein into a compound of Formula (II) as defined herein, the method comprising heating the compound of Formula (I) and a Lewis acidic heterogeneous reagent in an aprotic-solvent system to provide a compound of Formula (II), wherein the Lewis-acidic heterogeneous reagent is acidic alumina.

Disclosed herein are methods for converting cannabidiol, cannabidiolic acid and analogs thereof into Δ.sup.8-tetrahydrocannabinol, Δ.sup.8-tetrahydrocannabinolic acid and analogs thereof. In particular, there is provided a method for converting a compound of Formula (I) as defined herein into a compound of Formula (II) as defined herein, the method comprising heating the compound of Formula (I) and a Lewis acidic heterogeneous reagent in an aprotic-solvent system to provide a compound of Formula (II), wherein the Lewis-acidic heterogeneous reagent is acidic alumina.

Spent cannabis biomass is heated in stages, the first to remove water and volatile components, and the second to reclaim leftover cannabinoids. During a third, higher temperature stage, the biomass is subjected to a CO.sub.2 and/or water vapor treatment in order to obtain activated carbon with a desired porosity level.

Spent cannabis biomass is heated in stages, the first to remove water and volatile components, and the second to reclaim leftover cannabinoids. During a third, higher temperature stage, the biomass is subjected to a CO.sub.2 and/or water vapor treatment in order to obtain activated carbon with a desired porosity level.